Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jang, Heejoon | - |
dc.contributor.author | Yoon, Jun Sik | - |
dc.contributor.author | Park, Soo Young | - |
dc.contributor.author | Lee, Han Ah | - |
dc.contributor.author | Jang, Myoung-Jin | - |
dc.contributor.author | Kim, Seung Up | - |
dc.contributor.author | Sinn, Dong Hyun | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Kim, Hwi Young | - |
dc.contributor.author | Kim, Sung Eun | - |
dc.contributor.author | Jun, Dae Won | - |
dc.contributor.author | Yoon, Eileen L. | - |
dc.contributor.author | Sohn, Joo Hyun | - |
dc.contributor.author | Ahn, Sang Bong | - |
dc.contributor.author | Shim, Jae-Jun | - |
dc.contributor.author | Jeong, Soung Won | - |
dc.contributor.author | Cho, Yong Kyun | - |
dc.contributor.author | Kim, Hyoung Su | - |
dc.contributor.author | Nam, Joon Yeul | - |
dc.contributor.author | Lee, Yun Bin | - |
dc.contributor.author | Kim, Yoon Jun | - |
dc.contributor.author | Yoon, Jung-Hwan | - |
dc.contributor.author | Zoulim, Fabien | - |
dc.contributor.author | Lampertico, Pietro | - |
dc.contributor.author | Dalekos, George N. | - |
dc.contributor.author | Idilman, Ramazan | - |
dc.contributor.author | Sypsa, Vana | - |
dc.contributor.author | Berg, Thomas | - |
dc.contributor.author | Buti, Maria | - |
dc.contributor.author | Calleja, Jose Luis | - |
dc.contributor.author | Goulis, John | - |
dc.contributor.author | Manolakopoulos, Spilios | - |
dc.contributor.author | Janssen, Harry LA. | - |
dc.contributor.author | Papatheodoridis, George, V | - |
dc.contributor.author | Lee, Jeong-Hoon | - |
dc.date.accessioned | 2022-08-18T01:40:11Z | - |
dc.date.available | 2022-08-18T01:40:11Z | - |
dc.date.issued | 2022-06 | - |
dc.identifier.issn | 1542-3565 | - |
dc.identifier.issn | 1542-7714 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/61346 | - |
dc.description.abstract | Background & Aims Antiviral treatment from hepatitis B envelope antigen (HBeAg)-positive status may attenuate the integration of hepatitis B virus DNA into the host genome causing hepatocellular carcinoma (HCC). We investigated the impact of HBeAg status at the onset of antiviral treatment on the risk of HCC. Methods The incidence of HCC was evaluated in Korean patients with chronic hepatitis B who started entecavir or tenofovir in either HBeAg-positive or HBeAg-negative phase. The results in the Korean cohort were validated in a Caucasian PAGE-B cohort. Results A total of 9143 Korean patients (mean age, 49.2 years) were included: 49.1% were HBeAg-positive and 49.2% had cirrhosis. During follow-up (median, 5.1 years), 916 patients (10.0%) developed HCC. Baseline HBeAg positivity was not associated with the risk of HCC in the entire cohort or cirrhotic subcohort. However, in the non-cirrhotic subcohort, HBeAg positivity was independently associated with a lower risk of HCC in multivariable (adjusted hazard ratio [aHR], 0.41; 95% confidence interval [CI], 0.26–0.66), propensity score-matching (aHR, 0.46; 95% CI, 0.28–0.76), and inverse probability weighting analyses (aHR, 0.44; 95% CI, 0.28–0.70). In the Caucasian cohort (n = 719; mean age, 51.8 years; HBeAg-positive, 20.3%; cirrhosis, 34.8%), HBeAg-positivity was not associated with the risk of HCC either in the entire cohort or cirrhotic subcohort. In the non-cirrhotic subcohort, none of the HBeAg-positive group developed HCC, although the difference failed to reach statistical significance (aHR, 0.21; 95% CI, 0.00–1.67). Conclusions This multinational cohort study implies that HBeAg positivity at the onset of antiviral treatment seems to be an independent factor associated with a lower risk of HCC in patients with chronic hepatitis B without cirrhosis, but not in those with cirrhosis. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | W. B. Saunders Co., Ltd. | - |
dc.title | Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.cgh.2021.09.001 | - |
dc.identifier.scopusid | 2-s2.0-85119065401 | - |
dc.identifier.wosid | 000832942000021 | - |
dc.identifier.bibliographicCitation | Clinical Gastroenterology and Hepatology, v.20, no.6, pp 1343 - 1353.e16 | - |
dc.citation.title | Clinical Gastroenterology and Hepatology | - |
dc.citation.volume | 20 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1343 | - |
dc.citation.endPage | 1353.e16 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | TRANSIENT ELASTOGRAPHY | - |
dc.subject.keywordPlus | LIVER | - |
dc.subject.keywordPlus | DNA | - |
dc.subject.keywordPlus | INTEGRATION | - |
dc.subject.keywordPlus | PREDICTION | - |
dc.subject.keywordPlus | VALIDATION | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | EXPANSION | - |
dc.subject.keywordPlus | FIBROSIS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | Cumulative Incidence | - |
dc.subject.keywordAuthor | DNA | - |
dc.subject.keywordAuthor | Hepatitis B Virus | - |
dc.subject.keywordAuthor | Liver Cancer | - |
dc.subject.keywordAuthor | Neoplasm | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.